Objective 3 : Molecular and pharmacological intervention targeting chronic airway inflammation.
Th2-type airway inflammation is likely to be targeted by the use of monoclonal antibodies directed against IL5, IL4, IL13, IL33 and its receptor ST2, TSLP and others, currently under development in asthma and COPD and in patients with features of Asthma and COPD Overlap. Glucocorticoids are another insufficiently explored axis in case of exacerbation. Current associated biomarkers such as blood or sputum eosinophil count, or exhaled NO concentrations, suffer from several weaknesses that merit the identification of more stable and predictive biomarkers. Our team will develop the analysis of responders in clinics with the aim not only to identify molecular and functional biomarkers but also to determine resistance mechanisms in non-responder patients in order to find new therapeutic solutions.